CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma

Abstract

The aim of this study was to identify relevant biomarkers for the prognosis of glioma considering current molecular changes such as IDH mutation and 1p19q deletion. Gene expression profiling was performed using the TaqMan Low Density Array and hierarchical clustering using 96 selected genes in 64 patients with newly diagnosed glioma. The expression dataset was validated on a large independent cohort from The Cancer Genome Atlas (TCGA) database. A differential expression panel of 26 genes discriminated two prognostic groups regardless of grade and molecular groups of tumors: Patients having a poor prognosis with a median overall survival (OS) of 23.0 ± 9.6 months (group A) and patients having a good prognosis with a median OS of 115.0 ± 6.6 months (group B) (p = 0.007). Hierarchical clustering of the glioma TCGA cohort supported the prognostic value of these 26 genes (p < 0.0001). Among these genes, CHI3L1 and NTRK2 were identified as factors that can be associated with IDH status and 1p/19q co-deletion to distinguish between prognostic groups of glioma from the TCGA cohort. Therefore, CHI3L1 associated with NTRK2 seemed to be able to provide new information on glioma prognosis.

Expression and Prognostic Role of PLOD1 in Malignant Glioma

“…27 To improve prognosis prediction, other genes associated with IDH and 1p19q status need to be identified. 18,28 In this study, we revealed that PLOD1 expression was higher in glioma patients with IDH wildtype and 1p19q codeletion. Furthermore, PLOD1 was a supplementary prognostic marker for IDH1 and 1p19q status in predicting the outcome of glioma patients.…”

In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma

“…The OSMR (receptor for the cytokine Oncostatin M) is a regulator of brain tumor stem cells (BTSC) proliferation by mediating EGFR phosphorylation [ 40 ]. CHI3L1 can be associated with IDH status and 1p/19q co-deletion in patients with glioma [ 41 ].…”

Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer

“…NTRK1 promoted proliferation and metastasis of cancer cells and lead to poor prognosis in multiple cancers (13)(14)(15)(16)(17), while it suppressed cell proliferation in neuroblastoma (18). NTRK2 was shown to serve as an oncogene in multiple cancers (19)(20)(21)(22), and its increased expression was associated with poor outcome (23,24). Based on this, inhibition of NTRK2-encoded TRKB was shown to induce antitumor effects and cellular apoptosis (25,26).…”